Pharmaceutical formulations comprising tadalafil
Provided are stable, concentrated, and palatable solutions suitable for sublingual and/or transurethral administration containing tadalafil, with or without other active ingredients to address comorbidities, in a liquid vehicle or solvent selected from propylene carbonate, 2-pyrrolidone, dimethyl isosorbide, dimethyl acetamide, n-methyl-2-pyrrolidone, ethanol, water, oleic acid, and isopropyl myristate. The solutions have low irritancy for sublingual tissues and a-are compatible with commercial atomizers. The invention is further directed to methods of treating male erectile dysfunction and/or comorbidities by administering an effective amount of the pharmaceutical formulations comprising tadalafil, with or without other active ingredients, to a patient in need of such treatments.
1 . A composition, comprising:
(a) an active agent selected from:
(1) tadalafil, or a pharmaceutically acceptable salt thereof, or
(2) a combination of tadalafil, or a pharmaceutically acceptable salt thereof, with a therapeutic agent for treatment of comorbid diseases or conditions associated with erectile dysfunction selected from the group consisting of premature ejaculation, diabetes, cardiovascular disorders, hypertension, hyperlipidemia, obesity, depression, benign prostatic hyperplasia, hyperprolactinemic disorders, chronic obstructive pulmonary disease (COPD), lower urinary tract symptoms (LUTS), and testosterone deficiency; and
(b) a solvent comprising propylene carbonate, n-methyl-2-pyrrolidone, and glacial acetic acid, wherein the composition is in a sublingual, buccal, or transurethral dosage form, and wherein the sublingual dosage form is a liquisolid formulation.
2 . The composition according to claim 1 , wherein propylene carbonate is employed in an amount of about 10-60% by weight, and glacial acetic acid is employed in an amount of about 1-5% by weight.
3 . The composition according to claim 1 , wherein the solvent further comprises ethanol in an amount of about 0.1% to 10%.
4 . The composition according to claim 1 , further comprising one or more additives selected from the group consisting of surfactants, stabilizers, antioxidants, flavorings, sweeteners, and excipients.
5 . The composition according to claim 4 , wherein the one or more additive comprise a surfactant, wherein the surfactant is a poloxamer copolymer.
6 . The composition according to claim 1 , wherein the composition is a concentrated solution to be administered in a volume less than 0.2 ml.
7 . The composition according to claim 1 , wherein the liquisolid formulation is selected from liquisolid tablets or liquisolid capsules.
8 . The composition according to claim 1 , wherein the composition is an oral mist or spray.
9 . The composition according to claim 1 , wherein the active agent is a combination of tadalafil and a therapeutic agent for treatment of premature ejaculation, wherein said agent is selected from the group consisting of tramadol, cabergoline, apomorphine, dapoxetine, terazosin, paroxetine, ketamine, dextromethorphan, and oxytocin.
10 . The composition according to claim 1 , wherein the active agent is a combination of tadalafil and a therapeutic agent for treatment of hyperlipidemia, wherein said agent is atorvastatin.
11 . The composition according to claim 1 , wherein the active agent is a combination of tadalafil and a therapeutic agent for treatment of testosterone deficiency, wherein said agent is testosterone.
12 . The composition according to claim 1 , wherein the active agent is a combination of tadalafil and a therapeutic agent for treatment of diabetes.
13 . The composition according to claim 1 , wherein the active agent is a combination of tadalafil and a therapeutic agent for treatment of hypertension.
14 . A method for treatment of erectile dysfunction comprising administering to a patient in need of such treatment, an effective amount of a composition comprising:
an active agent selected from:
(1) tadalafil, or a pharmaceutically acceptable salt thereof, or
(2) a combination of tadalafil, or a pharmaceutically acceptable salt thereof, with a therapeutic agent for treatment of comorbid diseases or conditions associated with erectile dysfunction selected from the group consisting of premature ejaculation, diabetes, cardiovascular disorders, hypertension, hyperlipidemia, obesity, depression, benign prostatic hyperplasia, hyperprolactinemic disorders, chronic obstructive pulmonary disease (COPD), lower urinary tract symptoms (LUTS), and testosterone deficiency; and
a solvent comprising propylene carbonate, n-methyl-2-pyrrolidone, and glacial acetic acid, wherein the composition is in a sublingual, buccal, or transurethral dosage form, and wherein the sublingual dosage form is a liquisolid formulation.
15 . The method according to claim 14 , wherein the composition is a concentrated solution to be administered in a volume less than 0.2 ml.
16 . The method according to claim 14 , wherein the composition is an oral mist or spray.